9-position Substituted Patents (Class 514/180)
  • Publication number: 20120189713
    Abstract: The invention relates to novel monomers of Formula (I) useful for preparation of phase-separated biocompatible polymers or polymer compositions. These polymers or polymer compositions may be bioresorbable and/or biodegradable and have desirable mechanical properties, such as fracture and/or fatigue toughness, which have not been a primary design criteria for such polymers previously. The polymers or polymer compositions are useful in a variety of medical applications, such as in the fabrication of medical devices. Therefore, methods for preparing these polymers or polymer compositions and medical devices are also encompassed by this disclosure.
    Type: Application
    Filed: July 31, 2010
    Publication date: July 26, 2012
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Joachim B. Kohn, Durgadas Bolikal, Ramiro Rojas
  • Publication number: 20120177699
    Abstract: A preparation method of drug loaded emulsion is disclosed. The method comprises the steps of: preparing a non-self emulsifying O/W blank emulsion having no active ingredients; then, adding therapeutically effective amount of active ingredients to the 0/W blank emulsion, adjusting pH to distribute the active ingredients through the membrane to obtain the desired emulsion.
    Type: Application
    Filed: June 3, 2010
    Publication date: July 12, 2012
    Applicants: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Xinyong Tong, Haifeng Wang, Li Lu, Liang Chen, Yuan Shi
  • Publication number: 20120177717
    Abstract: Disclosed is a drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. Specifically disclosed is a sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.
    Type: Application
    Filed: February 16, 2012
    Publication date: July 12, 2012
    Applicant: TOHOKU UNIVERSITY
    Inventors: Toshiaki ABE, Nobuhiro NAGAI, Hirokazu KAJI, Takeaki KAWASHIMA, Matsuhiko NISHIZAWA, Koji NISHIDA
  • Patent number: 8211880
    Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-guage needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: July 3, 2012
    Assignee: Alcon Research, Ltd.
    Inventors: Bhagwati P. Kabra, Ruma Sarkar
  • Publication number: 20120157373
    Abstract: Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents.
    Type: Application
    Filed: February 29, 2012
    Publication date: June 21, 2012
    Applicant: MEDTRONIC, INC.
    Inventors: Paul Hsien-Fu Wu, Catherine E. Taylor, Linnus Cheruiyot, Jianwei Li, Terese A. Bartlett, Matt Bergan
  • Publication number: 20120148638
    Abstract: A dpi formulation comprises a solvate of beclomethasone with a non-cyclic, straight or branched C5-C7 hydrocarbon. The solvate particles are of size 0.5 to 10 microns and are obtained by crystallization of the steroid in the presence of ultrasound.
    Type: Application
    Filed: August 16, 2010
    Publication date: June 14, 2012
    Applicant: BREATH LIMITED
    Inventors: Ian Cameron Gardner McAffer, Peter Ernest Tasko, Susheela Ginafrancesco, Graham John Swift
  • Publication number: 20120148636
    Abstract: A process for producing micronized dispersed micro-particles and to micro-particles produced by this process.
    Type: Application
    Filed: June 24, 2010
    Publication date: June 14, 2012
    Inventors: Colin Berrido, Peter Rabke, Hans-Jurgen Huppert
  • Publication number: 20120135055
    Abstract: A dpi formulation comprises a solvate of beclomethasone and is substantially free of excipient and free of carrier. The solvate particles are of size 0.5 to 10 microns and are obtained by crystallization of the steroid in the presence of ultrasound.
    Type: Application
    Filed: August 16, 2010
    Publication date: May 31, 2012
    Applicant: BREATH LIMITED
    Inventors: Ian Cameron Gardner Mcaffer, Peter Ernest Tasko, Susheela Ginafrancesco, Graham John Swift
  • Publication number: 20120132204
    Abstract: An inhaler includes a first body member and a second body member fit closely together to form an inhaler body, and an outlet. The first body member has a medicament chamber containing a unit dose of powdered medicament. A seal such as a foil strip seals the medicament chamber and extends outwardly of the inhaler body. In use, one end of the seal can be grasped by a user and withdrawn, fully or partially, from the inhaler body, to release the powdered medicament from the medicament chamber. The second body member includes a medicament collection well in which the medicament is collected upon its release from the medicament chamber. The medicament collection well forms part of an airway connecting into the outlet. In use, air can be drawn by inhalation at the outlet to entrain the powder medicament in the collection well for inhalation by a user.
    Type: Application
    Filed: February 9, 2012
    Publication date: May 31, 2012
    Applicant: INNOVATA BIOMED LIMITED
    Inventors: Samuel W. Lucking, Glen P. Martyn
  • Publication number: 20120128741
    Abstract: The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.
    Type: Application
    Filed: July 23, 2010
    Publication date: May 24, 2012
    Applicant: Carbylan Biosurgery, Inc.
    Inventors: David M. Gravett, George Y. Daniloff, Pingren He
  • Publication number: 20120129824
    Abstract: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.
    Type: Application
    Filed: November 2, 2011
    Publication date: May 24, 2012
    Inventors: Arturo Angel, Gordon Dow
  • Publication number: 20120121684
    Abstract: Implantable medical devices are disclosed. The devices comprise a coating comprising an interpenetrating network or semi-interpenetrating network. The interpenetrating network or semi-interpenetrating network comprises poly(ethylene glycol) and an aliphatic polyester copolymer. A method of using the implantable device is also provided.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 17, 2012
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Mikael Trollsas, Florencia Lim, Syed F.A. Hossainy
  • Patent number: 8178519
    Abstract: The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.
    Type: Grant
    Filed: November 16, 2005
    Date of Patent: May 15, 2012
    Assignee: Norton Healthcare Limited
    Inventors: John Miller, Paul Ronald, Adrian Ashley, Paul Lamb, Donald MacDonald, Martin Oliver, Matthew Pollard
  • Publication number: 20120116216
    Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.
    Type: Application
    Filed: January 17, 2012
    Publication date: May 10, 2012
    Applicant: Alcon Research, Ltd.
    Inventors: Bhagwati P. Kabra, Ruma Sarkar
  • Publication number: 20120093759
    Abstract: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.
    Type: Application
    Filed: November 17, 2011
    Publication date: April 19, 2012
    Inventor: David J. Vachon
  • Publication number: 20120088745
    Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
    Type: Application
    Filed: October 11, 2011
    Publication date: April 12, 2012
    Inventors: C. Simone Fishburn, David Lechuga-Ballesteros, Tacey Viegas, Mei-Chang Kuo, Yuan Song, Hema Gursahani, Chester Leach
  • Publication number: 20120087957
    Abstract: Process for preparing sterile suspensions for inhalation comprising an active ingredient insoluble in water and wherein at least 80% of the particles of said active ingredient have a diameter between 3 and 5 ?m, comprising the following stages: dissolving the active ingredient in the minimum quantity of an alcoholic solvent, optionally in the presence of a polyol and adding at least one surfactant, filtering the solution obtained in the previous stage through a sterilizing filter, adding the solution from stage (b) to sterile water under sonication to directly obtain a suspension wherein the particles have a reduced diameter.
    Type: Application
    Filed: December 21, 2011
    Publication date: April 12, 2012
    Applicant: CHIESI FARMACEUTICAL S.P.A.
    Inventors: Celestino RONCHI, Giancarlo CESCHEL
  • Publication number: 20120082659
    Abstract: Disclosed are compositions and methods related to new targets for cancer treatment.
    Type: Application
    Filed: October 12, 2011
    Publication date: April 5, 2012
    Inventors: Hartmut Land, Helene R. McMurray, Erik R. Sampson
  • Publication number: 20120070467
    Abstract: The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.
    Type: Application
    Filed: July 15, 2011
    Publication date: March 22, 2012
    Applicant: Corinthian Ophthalmic, Inc.
    Inventors: Bernard L. Ballou, JR., Mark Packer, Russell John Mumper, Tsontcho Inachulev
  • Publication number: 20120065178
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Application
    Filed: November 17, 2011
    Publication date: March 15, 2012
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Publication number: 20120059462
    Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
    Type: Application
    Filed: November 15, 2011
    Publication date: March 8, 2012
    Inventor: Vernon G. Wong
  • Patent number: 8128909
    Abstract: Disclosed is a process for the preparation of sterile aqueous suspensions based on active ingredients in the form of micronised crystalline particles designed for administration by inhalation. In particular, a process for the preparation of sterile aqueous suspensions based on pharmaceutical active ingredients in the form of crystalline hydrates is disclosed.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: March 6, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Andrea Capocchi, Fausto Pivetti
  • Publication number: 20120053161
    Abstract: Solution formulations containing a corticosteroid, cyclodextrin, and xanthan gum are disclosed. The formulations are intended for topical application to the eye, ear, or nose.
    Type: Application
    Filed: July 28, 2009
    Publication date: March 1, 2012
    Applicant: Novartis AG
    Inventors: Ernesto J. Castillo, Huixiang Zhang, Glenn D. Stafford, Wesley Wehsin Han
  • Publication number: 20120046264
    Abstract: Methods for commercial production of transdermal formulations comprising a hormone compound are provided. In particular, methods for commercial scale production under an inert atmosphere of a transdermal formulation comprising a therapeutically effective amount of a hormone, preferably a testosterone compound, useful for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women are provided.
    Type: Application
    Filed: August 17, 2011
    Publication date: February 23, 2012
    Applicant: BIOSANTE PHARMACEUTICALS, INC.
    Inventors: Stephen Simes, Linda Lieb
  • Publication number: 20120046263
    Abstract: The present invention includes methods of influencing the sex chromosome ovulated by a female bird and altering the sex ratio in avian offspring by altering the exposure of an ovulating female bird to one or more stress hormones.
    Type: Application
    Filed: March 1, 2010
    Publication date: February 23, 2012
    Applicant: Univeristy of Georgia Research
    Inventor: Kristen J. Navara
  • Patent number: 8119619
    Abstract: Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: February 21, 2012
    Assignee: Umecrine AB
    Inventors: Torbjörn Bäckström, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
  • Publication number: 20120040930
    Abstract: The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.
    Type: Application
    Filed: January 13, 2006
    Publication date: February 16, 2012
    Inventors: Catherine Guillou, Jean-Yves Lallemand, Thibault Sauvaítre, Jordi Molgo, Denyse Herlem, Daniel Guenard, Françoise Khuong-Huu
  • Publication number: 20120040938
    Abstract: Provided here in are, inter alia, methods of determining whether a patient is resistant or sensitive to glucocorticoid therapy.
    Type: Application
    Filed: March 4, 2009
    Publication date: February 16, 2012
    Applicant: SHRINERS HOSPITAL FOR CHILDREN
    Inventors: Kiho Cho, David G. Greenhalgh
  • Publication number: 20120040945
    Abstract: Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.
    Type: Application
    Filed: February 3, 2010
    Publication date: February 16, 2012
    Applicant: ACTIVAERO GMBH RESEARCH & DEVELOPMENT
    Inventors: Bernard Muellinger, Thomas Hofmann, Gerhard Scheuch, Philipp Kroneberg
  • Publication number: 20120035107
    Abstract: Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.
    Type: Application
    Filed: September 24, 2011
    Publication date: February 9, 2012
    Inventors: Wouter E. Roorda, Stephen D. Pacetti
  • Publication number: 20120035148
    Abstract: Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component.
    Type: Application
    Filed: September 19, 2011
    Publication date: February 9, 2012
    Applicant: ALLERGAN, INC
    Inventor: Scott M. Whitcup
  • Publication number: 20120035146
    Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.
    Type: Application
    Filed: October 12, 2011
    Publication date: February 9, 2012
    Inventors: Vernon G. Wong, Mae W. L. Hu
  • Publication number: 20120028944
    Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.
    Type: Application
    Filed: January 27, 2011
    Publication date: February 2, 2012
    Applicant: OCULIS EHF
    Inventors: Thorsteinn Loftsson, Einar Stefansson
  • Publication number: 20120028943
    Abstract: The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of fluticasone propionate, used in treating skin inflammation c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, and a corticosteroid in the form of fluticasone propionate, are incorporated in cream base for use in treating skin inflammation due to allergy & itching & wounds on human skin involving contacting human skin with the above identified composition.
    Type: Application
    Filed: April 5, 2010
    Publication date: February 2, 2012
    Applicant: APEX LABORATORIES PRIVATE LIMITED
    Inventors: Vanangamudi Subramaniam Sulur, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Haridas Sankar, Kausik Ghosh
  • Publication number: 20120021036
    Abstract: The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartments which in unison function as a composite nanostructure. In one embodiment, the nanoparticles of the invention comprise a combination of polymer core/lipid bilayer interface which incorporate covalently attached lipid-vascular targeting ligands. These composite nanoparticles can deliver highly effective and selective payloads for diagnostic, prophylactic or therapeutic applications.
    Type: Application
    Filed: January 14, 2010
    Publication date: January 26, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Bharat Majeti, Eric Murphy, Wolfgang Wrasidlo, David Cheresh
  • Publication number: 20120020951
    Abstract: Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.
    Type: Application
    Filed: July 15, 2011
    Publication date: January 26, 2012
    Inventors: Harold Michael Shepard, Curtis Thompson, Xiaoming Li, Gregory I. Frost
  • Publication number: 20120022034
    Abstract: Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
    Type: Application
    Filed: September 21, 2011
    Publication date: January 26, 2012
    Applicant: ALLERGAN, INC.
    Inventor: Vernon G. Wong
  • Publication number: 20120015924
    Abstract: The process comprises delivering a spray solution comprising an active agent and a matrix material in an organic solvent to a spray-drying apparatus, atomizing the spray solution into droplets within the spray-drying apparatus to remove at least a portion of the organic solvent from the droplets to form a plurality of particles, and collecting the particles. The spray solution may be formed by forming a feed suspension comprising the active agent, the matrix material, and the organic solvent, wherein the feed suspension is at a temperature T1, and directing the feed suspension to a heat exchanger, thereby increasing the temperature of the feed suspension to a temperature T2, wherein T2 is greater than T1, and the spray solution is at a pressure greater than the vapor pressure of the organic solvent at T2, such that the active agent and matrix material are soluble in the organic solvent at T2.
    Type: Application
    Filed: March 19, 2010
    Publication date: January 19, 2012
    Inventors: Dwayne T. Friesen, David D. Newbold, John M. Baumann, Devon B. Dubose, Douglas L. Millard
  • Publication number: 20120003291
    Abstract: Medical devices comprising nanobeads encapsulating one or more bioactive agents and methods of use thereof are provided.
    Type: Application
    Filed: September 13, 2011
    Publication date: January 5, 2012
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Charles H. Craig, John E. Papp, Dudley Jayasinghe, Lionel G. Hines, Dennis Orosa
  • Publication number: 20120003282
    Abstract: Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof.
    Type: Application
    Filed: March 3, 2010
    Publication date: January 5, 2012
    Inventors: Warren K. Miller, David T. Vodak, Daniel E. Dobry, David K. Lyon, Dwayne T. Friesen, Michael M. Morgen, Corey J. Bloom, Daniel t. Smithey
  • Publication number: 20120004205
    Abstract: The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products induced by IL-13.
    Type: Application
    Filed: December 1, 2009
    Publication date: January 5, 2012
    Applicant: Cincinnati Children's Hospital Medical Center
    Inventor: Marc Elliott Rothenberg
  • Publication number: 20110319377
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: July 25, 2011
    Publication date: December 29, 2011
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OTONOMY, INC.
    Inventors: Jay Lichter, Benedikt Vollrath, Andrew M. Trammel, Sergio G. Durón, Fabrice Piu, Luis A. Dellamary, Qiang Ye, Carl Lebel, Michael Christopher Scaife, Jeffrey P. Harris
  • Patent number: 8080263
    Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: December 20, 2011
    Assignee: Novartis AG
    Inventors: Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov, Jeffry G. Weers, Ernest G. Schutt
  • Publication number: 20110305743
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Application
    Filed: August 19, 2011
    Publication date: December 15, 2011
    Inventors: Jane-Guo SHIAH, Rahul BHAGAT, Wendy M. BLANDA, Thierry NIVAGGIOLI, Lin PENG, David CHOU, David A. WEBER
  • Publication number: 20110301136
    Abstract: The present invention relates to the diuretic effects of nitrate esters of corticoid compounds. A patient in heart failure may be treated by administering a therapeutically effective dosage of a pharmaceutical composition comprising a nitrate ester of corticoid compound as a diuretic having the general formula B—X1—NO2. A method of improving kidney function by administering a therapeutically effective dosage of a pharmaceutical composition having a nitrate ester of corticoid compound of the same formula is also described.
    Type: Application
    Filed: June 2, 2011
    Publication date: December 8, 2011
    Inventors: Chao Liu, Kunshen Liu
  • Publication number: 20110301135
    Abstract: The invention relates to nonaqueous pharmaceutical preparations comprising a glucocorticoid ester and an acid, and to the stabilization of glucocorticoid esters in such preparations by acids.
    Type: Application
    Filed: November 29, 2010
    Publication date: December 8, 2011
    Applicant: BAYER ANIMAL HEALTH GMBH
    Inventors: DIRK MERTIN, Iris Heep, Georg Schulte, Ulrike Umgelder, Gert Daube, Ernst B+e,uml o+ee ttcher
  • Publication number: 20110293689
    Abstract: The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity.
    Type: Application
    Filed: August 11, 2011
    Publication date: December 1, 2011
    Inventors: Robert L. Cleek, Michael D. Daly, Krzysztof R. Pietrzak
  • Publication number: 20110294717
    Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.
    Type: Application
    Filed: December 15, 2010
    Publication date: December 1, 2011
    Inventors: Mir M. Ali, Abhimanyu Sabnis, David Dewitt, Greg Troiano, James Wright, Maria Figueiredo, Michael Figa, Tina Van Geen Hoven, Young-Ho Song, Jason Auer, Tarikh C. Campbell
  • Publication number: 20110288062
    Abstract: A polymer system useful for in vivo delivery of a therapeutic agent is provided. The polymer system comprises a biocompatible biodegradable polymeric backbone that is capable of a reversible stimuli-induced transition from liquid to gel.
    Type: Application
    Filed: April 22, 2011
    Publication date: November 24, 2011
    Inventors: Heather Sheardown, Scott Fitzpatrick, M.A. Jafar Mazumder
  • Patent number: 8063031
    Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: November 22, 2011
    Assignee: Allergan, Inc.
    Inventors: Vernon G. Wong, Mae W. L. Hu